These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 26312707)
21. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis. Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452 [TBL] [Abstract][Full Text] [Related]
22. Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α. Langkilde A; Olsen LC; Sætrom P; Drabløs F; Besenbacher S; Raaby L; Johansen C; Iversen L PLoS One; 2016; 11(12):e0167437. PubMed ID: 28005985 [TBL] [Abstract][Full Text] [Related]
23. Biological therapy induces expression changes in Notch pathway in psoriasis. Skarmoutsou E; Trovato C; Granata M; Rossi GA; Mosca A; Longo V; Gangemi P; Pettinato M; D'Amico F; Mazzarino MC Arch Dermatol Res; 2015 Dec; 307(10):863-73. PubMed ID: 26319047 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice. Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203 [TBL] [Abstract][Full Text] [Related]
25. Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-TNF-α monoclonal antibody: an observational multicenter study. Ardigò M; Agozzino M; Longo C; Lallas A; Di Lernia V; Fabiano A; Conti A; Sperduti I; Argenziano G; Berardesca E; Pellacani G J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2363-8. PubMed ID: 26299420 [TBL] [Abstract][Full Text] [Related]
28. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440 [TBL] [Abstract][Full Text] [Related]
29. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. Pina T; Corrales A; Lopez-Mejias R; Armesto S; Gonzalez-Lopez MA; Gómez-Acebo I; Ubilla B; Remuzgo-Martínez S; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA J Dermatol; 2016 Nov; 43(11):1267-1272. PubMed ID: 27062420 [TBL] [Abstract][Full Text] [Related]
30. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Gniadecki R; Kragballe K; Dam TN; Skov L Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290 [TBL] [Abstract][Full Text] [Related]
31. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. Lombardi G; Perego S; Sansoni V; Diani M; Banfi G; Altomare G BMJ Open; 2016 Dec; 6(12):e011941. PubMed ID: 27940624 [TBL] [Abstract][Full Text] [Related]
32. TNF inhibitors for psoriasis. Chima M; Lebwohl M Semin Cutan Med Surg; 2018 Sep; 37(3):134-142. PubMed ID: 30215629 [TBL] [Abstract][Full Text] [Related]
33. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy. Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1995-2001. PubMed ID: 25823684 [TBL] [Abstract][Full Text] [Related]
34. Biologic therapies for psoriasis. de Felice C; Ardigo M; Berardesca E J Rheumatol Suppl; 2009 Aug; 83():62-4. PubMed ID: 19661545 [TBL] [Abstract][Full Text] [Related]
35. High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti-TNF-α Therapy. Sanz-Martínez MT; Moga E; Sánchez Martínez MA; Zamora Atenza C; Vidal S; Juárez C; Puig L J Invest Dermatol; 2020 Jun; 140(6):1176-1183. PubMed ID: 31778714 [TBL] [Abstract][Full Text] [Related]
36. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis. Campanati A; Orciani M; Gorbi S; Regoli F; Di Primio R; Offidani A Br J Dermatol; 2012 Jul; 167(1):68-76. PubMed ID: 22356229 [TBL] [Abstract][Full Text] [Related]
37. Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood. Chow M; Lai K; Ahn R; Gupta R; Arron S; Liao W J Drugs Dermatol; 2016 Aug; 15(8):988-94. PubMed ID: 27538000 [TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804 [TBL] [Abstract][Full Text] [Related]
39. Biologic Therapy in Psoriasis: Safety Profile. Campanati A; Ganzetti G; Giuliodori K; Molinelli E; Offidani A Curr Drug Saf; 2016; 11(1):4-11. PubMed ID: 26463245 [TBL] [Abstract][Full Text] [Related]
40. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis. Yanaba K; Umezawa Y; Honda H; Sato R; Chiba M; Kikuchi S; Asahina A; Nakagawa H J Dermatol; 2016 Apr; 43(4):443-4. PubMed ID: 26662275 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]